Abstract
In Ethiopia, a breast cancer diagnosis is associated with a prognosis significantly worse than that of Europe and the US. Further, patients presenting with breast cancer in Ethiopia are far younger, on average, and patients are typically diagnosed at very late stages, relative to breast cancer patients of European descent. Emerging data suggest that a large proportion of Ethiopian patients have hormone-positive (ER +) breast cancer. This is surprising given 1) the aggressive nature of the disease, 2) that African Americans with breast cancer frequently have triple negative breast cancer (TNBC), and 3) these patients typically receive chemotherapy, not hormone-targeting drugs. To further examine the similarity of Ethiopian breast tumors to those of African Americans or of those of European descent, we sequenced matched normal and tumor tissue from Ethiopian patients from a small pilot collection. We identified mutations in 615 genes across all three patients, unique to the tumor tissue. Across this analysis, we found far more mutations shared between Ethiopian patient tissue and White patients (103) than we did comparing to African Americans (3). Several mutations were found in extracellular matrix encoding genes with known roles in tumor cell growth and metastasis. We suggest future mechanistic studies on this disease focus on these genes first, toward finding new treatment strategies for breast cancer patients in Ethiopia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a seed grant awarded to SRP and CCB from the Models 2 Medicine Center, part of the Institute for Applied Life Sciences at UMass Amherst. ADS was supported by a National Science Foundation Graduate Research Fellowship (Award 1451512). This work was supported by an NSF CAREER (DMR1454806), and NIH grants R21CA223783 and DP2CA186573 awarded to SRP. Funding was also provided in part by a generous donation from the Giglio Family to the Wallace H. Coulter Department of Biomedical Engineering (MOP). SRP was also supported by a grant from the Jane Koskinas Ted Giovanis Foundation for Health and Policy. SRP is an Armstrong Professional Development Professor.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB 17-88 from UMass Amherst has determined this study is exempt from human subject research approval because the project does not involve intervention or interaction with individuals OR does not use identifiable private information.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is currently being archived and will be made available soon.
